Search results
Found 2376 matches for
The University of Oxford has today announced an agreement with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate currently being trialled by the Oxford Vaccine Group.
Group B streptococcus
Group B streptococcus (GBS) is an important cause of meningitis and sepsis in babies, affecting approximately 1 in 1000 live births in the United Kingdom.
Nepal Pneumococcal Impact Assessment Project
Pneumonia accounts for 15% of deaths among children under-5 years of age globally. The burden of disease is especially high in South Asia, where one in four children suffer an episode of pneumonia every year. Streptococcus pneumoniae is one of the most significant causative pathogens of pneumonia and other serious invasive diseases.
Vaccines against Ebola Virus disease
The devastating 2013-2015 outbreak of Ebola Virus disease in West Africa provided the impetus for acceleration of multiple programmes of Ebola Vaccine development.
Development and evaluation of vaccines against group B meningococcal disease (MenB)
Neisseria meningitidis (Meningitis) is the cause of around 500,000 cases of meningitis and septicaemia every year and disproportionately affects children under two years. We have created new vaccines against MenB. To do this, we have characterised their immunogenicity, identified the optimal vaccine regimen, and evaluated their protective efficacy.
Respiratory syncytial virus (RSV)
RSV infection is the most important cause of hospitalisation in infants and one of the leading global causes of infant mortality and as such its prevention through immunisation is a public health priority.
Vaccine Knowledge Project
Independent information about vaccines and infectious diseases ( vaccineknowledge.ox.ac.uk )
Systems Vaccinology/Systems Biology
Our aim is to understand disease pathogenesis and host responses to infection and vaccination.